Welcome to our dedicated page for Sonoma Pharmaceu SEC filings (Ticker: SNOA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
If you’ve tried extracting how much Sonoma Pharmaceuticals allocates to HOCl research in its latest filings, you’ve felt the frustration of combing through dense disclosures. Miss a footnote and your model is off. Stock Titan eliminates that risk.
The moment EDGAR releases a document, we capture it—whether it’s a Sonoma Pharmaceuticals quarterly earnings report 10-Q filing, an 8-K on new Microcyn clearances, or a Form 4 trade notice. Our AI then produces Sonoma Pharmaceuticals SEC filings explained simply: plain-English summaries, red-flag alerts, and side-by-side metric trends. Need details from the Sonoma Pharmaceuticals annual report 10-K simplified version? One click. Watching for Sonoma Pharmaceuticals insider trading Form 4 transactions? Real-time dashboards surface every Sonoma Pharmaceuticals Form 4 insider transactions real-time.
Professionals use the page to:
- Run instant Sonoma Pharmaceuticals earnings report filing analysis that links HOCl segment sales to clinical-trial spending.
- Track Sonoma Pharmaceuticals executive stock transactions Form 4 ahead of key FDA feedback.
- Review the Sonoma Pharmaceuticals proxy statement executive compensation to see how pay aligns with pipeline milestones.
- Digest Sonoma Pharmaceuticals 8-K material events explained modules within minutes of publication.
By understanding Sonoma Pharmaceuticals SEC documents with AI, you’ll spot cash-burn trends, distribution-deal impacts, and manufacturing risks without navigating hundreds of pages. All filings, all insights—updated continuously.
Form 4 overview: Sonoma Pharmaceuticals, Inc. (Ticker: SNOA) reported an insider equity transaction by Executive VP & COO Bruce Thornton on 06/19/2025. The filing discloses a grant of 13,500 Restricted Stock Units (RSUs), each representing the contingent right to receive one share of common stock at no cost to the executive.
Key terms of the award:
- Transaction code: “A” (acquisition) – the shares were granted, not purchased on the open market.
- Exercise/Conversion price: $0.00, indicating a purely compensatory award.
- Vesting schedule: The RSUs vest in full on the third anniversary of the 06/19/2025 grant date or sooner upon a change-of-control event, as noted in the explanatory footnotes.
Following the grant, Mr. Thornton’s total derivative holdings increased to 32,191 RSUs. No non-derivative common shares were reported in Table I, and no sales or dispositions occurred. The filing was signed on 06/20/2025 by an attorney-in-fact and reflects routine executive compensation rather than a market transaction.
Investor takeaway: The insider’s equity exposure has risen through a standard RSU award, signalling continued alignment of management incentives with shareholder value but does not, by itself, provide insight into the company’s near-term financial performance.
Form 4 overview – Sonoma Pharmaceuticals (SNOA)
On 19 June 2025 Sonoma Pharmaceuticals filed a Form 4 detailing an equity-compensation grant to Chief Financial Officer Jerome J. Dvonch. The company awarded the executive 13,500 restricted stock units (RSUs), each convertible into one share of common stock at no exercise price. The award vests in full on the third anniversary of the grant date or earlier upon a change of control, aligning long-term incentives with shareholder value.
Following the grant, Mr. Dvonch’s derivative holdings increased to 25,515 RSUs, all held directly. No open-market purchase or sale of common stock occurred, and therefore the transaction has no immediate cash impact on the executive, the company, or existing shareholders; any dilution will materialise only when the RSUs convert to shares. The filing is a routine disclosure required under Section 16(a) and does not signal a material change in Sonoma Pharmaceuticals’ operations, strategy, or near-term financial outlook.
Schedule 13D Filing Overview – Pineapple Financial Inc. ("PAPL")
Pineapple Financial Inc. has received a Schedule 13D from Marin Kendall Leo, the company’s President and Chief Operating Officer. The filing, triggered on 16 June 2025 and signed on 24 June 2025, discloses the acquisition and current beneficial ownership of 2,077,798 common shares.
Ownership Details
- Represents 10.34 % of the issuer’s 20,092,020 outstanding common shares (per proxy dated 27 May 2025).
- Shares were purchased with the executive’s personal funds (Source of Funds: PF).
- Mr. Leo holds sole voting and sole dispositive power over the entire position; no shared power is reported.
Intent
The shares are held for investment purposes. The filer states that, aside from ordinary investment intent, there are no current plans or proposals that would result in mergers, asset sales, changes in the board, capitalization, or any other corporate actions listed under Item 4 of Schedule 13D.
Regulatory & Legal Background
- No criminal convictions or civil proceedings are reported for the past five years.
- No contracts, arrangements, or understandings exist with other parties regarding the shares, beyond what is disclosed.
Key Takeaways for Investors
- Disclosure lifts insider ownership visibility, confirming that a senior officer controls a double-digit stake.
- The absence of activist intent suggests a passive, confidence‐oriented holding rather than an imminent strategic shift.
FAQ
What is the current stock price of Sonoma Pharmaceu (SNOA)?
What is the market cap of Sonoma Pharmaceu (SNOA)?
What products does Sonoma Pharmaceuticals develop?
How does the patented Microcyn technology work?
Which therapeutic areas does Sonoma Pharmaceuticals target?
In which markets does Sonoma Pharmaceuticals operate?
What regulatory clearances have Sonoma Pharmaceuticals achieved?
How does Sonoma differentiate itself from competitors in the HOCl market?
What benefits do Sonoma’s products offer to consumers?
